Engimmune Therapeutics

Our one and only Joseph Taft is presenting at the Festival of Biologics Basel today, where he will discuss our unique ML-guided approaches to engineer specTR engager molecules to very high affinities and specificities. By engineering these properties, Joe and our TCR engineering team (Tamara Lichtenstein, Chiara Lamanna, Valentin Junet) ensure that our specTR molecules target tumour cells (and very soon, inflamed tissue) with extreme accuracy to develop highly targeted immunotherapies in oncology and immune-mediated disease. #teameffort #TCR #immunotherapy #precisionmedicine

Our one and only Joseph Taft is presenting at the Festival of Biologics Basel today, where he will discuss our unique ML-guided approaches to engineer specTR engager molecules to very high affinities and specificities. By engineering these properties, Joe and our TCR engineering team (Tamara Lichtenstein, Chiara Lamanna, Valentin Junet) ensure that our specTR molecules target tumour cells (and very soon, inflamed tissue) with extreme accuracy to develop highly targeted immunotherapies in oncology and immune-mediated disease. #teameffort #TCR #immunotherapy #precisionmedicine

It has come to our attention that scammers are fraudulently offering jobs at our company, presumably with the goal of obtaining personal information from victims. It is not our policy to contact candidates directly without them having applied to an open position first (e.g., on Linkedin). Related to this, we currently have no open positions. Please be careful not share any information with individuals impersonating employees at Engimmune Therapeutics. Engimmune Therapeutics currently uses a single domain, namely “@engimmune.com” (with a double “m”). Any email addresses not ending in that domain do not belong to Engimmune Therapeutics or any of its employees. Thank you. #phishingalert

Last week, our CEO Lars Nieba and CSO Rodrigo Vazquez-Lombardi had a conversation with Handelsblatt about how Engimmune’s soluble TCR drug candidates redirect the immune system against solid tumours.   They also discussed how coupling advanced protein engineering methods with AI helps us identify extremely rare drug candidates that are both potent and safe. By leveraging these technologies, we continue with our mission to develop effective targeted immunotherapies to help patients suffering from cancers for which limited treatment options exist.   Video (English), Article (German). Published Friday May 31, 2024. https://lnkd.in/ekdX4cRZ

🧬 👨🔬 Spring of Science at Engimmune 👩🔬 🧪   We very much look forward to presenting a number of talks on Engimmune’s approach to AI-driven development of specificity- and affinity-enhanced soluble T cell receptors (specTRs) targeting oncology indications of high unmet medical need.   Our colleagues Sébastien Lalevée (Principal Scientist), Rodrigo Vazquez-Lombardi (CSO), Lars Nieba (CEO) and Kenneth Crook (Head of Translational Medicine) will be presenting at the Immuno-oncology Summit Europe (London, 24 April), TCR-based Therapies for Solid Tumours Summit (Boston, 25 April), Nexus Drug Discovery Conference (Basel, 25 April) and Immuno 2024 (London, 26 April), respectively. Make sure to reach out to our team members at these events or online to learn more about our innovative technologies and advancing pipeline.   Safe travels to Seb, Roddy and Ken! And a pleasant commute for Lars! https://lnkd.in/dgE7-xS https://lnkd.in/gF2zkg8 https://lnkd.in/ebgYvmRm https://lnkd.in/dCeaHGqC

Our Head of Translational Medicine Kenneth Crook will be presenting Engimmune's AI-guided platform technologies for soluble TCR drug development at Immuno 2024 on April 25-26. In this video, we get his perspective on current trends in immuno-oncology and on how specTR molecules (specificity- and affinity-enhanced soluble TCR engagers) can address key challenges in the treatment of solid tumours. https://lnkd.in/eP7XteCS

Yesterday, our CEO Dr. Lars Nieba presented Engimmune’s AI-guided technologies and soluble TCR drug pipeline at the Pitch&Connect event at our very own home Switzerland Innovation Park Basel Area. Thank you SIP for the wonderful event and to all of you that attended for the great questions and discussions! Stay tuned for more developments!

Yesterday, our CEO Dr. Lars Nieba presented Engimmune’s AI-guided technologies and soluble TCR drug pipeline at the Pitch&Connect event at our very own home Switzerland Innovation Park Basel Area. Thank you SIP for the wonderful event and to all of you that attended for the great questions and discussions! Stay tuned for more developments!

Great to see our CEO Lars Nieba quoted in Labiotech.eu talking about the future of cancer care, including the huge potential of T-cell receptor (TCR) based therapies. Engimmune Therapeutics is at the forefront of developing soluble TCRs. “These tumor-infiltrating drugs will be of particular help in tackling advanced cancers, where tumors are bigger and more developed,” said Nieba. Read the full article here: https://lnkd.in/deaSPBAB

What does the future of cancer treatment look like in 2034? 🔮 As we observe 🎗️ World Cancer Day today, we take a look at the different kinds of treatments and ongoing research that are poised to make a difference ten years down the line. 📅 From immunotherapy to precision medicine to cancer vaccines 💉, there is hope that cancer care will change for the better, although making the process for receiving treatment more affordable needs to be addressed. 💵 Labiotech spoke to experts like John Maher, CSO of Leucid Bio, Germo Gericke, CMO of Ariceum Therapeutics, Catherine Pickering, CEO of iOnctura, Lars Nieba, CEO of Engimmune Therapeutics, Liam Tremble, Principal Scientist at Poolbeg Pharma plc, and Jason Loveridge, CEO of 4SC AG, to find out more about what the future of cancer care holds in store. Read our latest article to find out! 👇 https://lnkd.in/deaSPBAB #cancerresearch #futureofcancertreatment #worldcancerday #immunotherapyadvancements #precisionmedicine #cancervaccines #affordabletreatment #medicalinnovation #expertinsights